KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Assets (2016 - 2025)

Astrazeneca (AZN) has 3 years of Assets data on record, last reported at $114.1 billion in Q4 2025.

  • For Q4 2025, Assets rose 9.65% year-over-year to $114.1 billion; the TTM value through Dec 2025 reached $114.1 billion, up 9.65%, while the annual FY2025 figure was $114.1 billion, 9.65% up from the prior year.
  • Assets reached $114.1 billion in Q4 2025 per AZN's latest filing, up from $104.0 billion in the prior quarter.
  • Across five years, Assets topped out at $114.1 billion in Q4 2025 and bottomed at $313.0 million in Q4 2023.
  • Average Assets over 3 years is $72.8 billion, with a median of $104.0 billion recorded in 2024.
  • Peak YoY movement for Assets: surged 33138.02% in 2024, then rose 9.65% in 2025.
  • A 3-year view of Assets shows it stood at $313.0 million in 2023, then soared by 33138.02% to $104.0 billion in 2024, then grew by 9.65% to $114.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $114.1 billion in Q4 2025, $104.0 billion in Q4 2024, and $313.0 million in Q4 2023.